Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Provided By GlobeNewswire

Last update: Jun 4, 2025

June 4, 2025

Biodexa Announces Recruitment of First Patient
in Phase 2 Study of Tolimidone in Type 1 Diabetes

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes (“T1D”).